Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04231565 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.

Study acronym: ALTHBV
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 1, 2024 (before its estimated June 1, 2024 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 100 to 200v5 Show 5 more changesShow less
    • Primary completion date: Jul 1, 2022 to Jun 1, 2024
    • Primary endpoint revised
    • Study completion date: Dec 31, 2022 to Jul 1, 2027
    • Start date: Jan 31, 2021 to Jun 4, 2020
    • Secondary endpoints: 3 to 4
  2. Start date changed from estimate of Jul 31, 2021 to Jan 31, 2021v4
  3. Start date: Mar 31, 2020 to Jul 31, 2021v3
  4. Start date: Jan 31, 2020 to Mar 31, 2020v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus DNA.
Trial Details
NCT Number NCT04231565
Lead Sponsor Third Affiliated Hospital, Sun Yat-Sen University
Conditions
(from sponsor)		 Hepatitis B Virus
Related terms Hepatitis B
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov